dual glp 1 glucagon receptor agonists Main physiological actions of the GIP and GLP-1 agonist PDB-101: Molecule of the Month:

[DOI] [PubMed] [Google Scholar] 299.Mandoe M.J., Hansen K.B., Hartmann B., Rehfeld J.F., Holst J.J., Hansen H.S

Exenatide Once Weekly Versus Placebo in Parkinsons Disease: A Randomised, Double-Blind, Placebo-Controlled Trial

Symptoms of IIH often stem from elements other than increased intracranial pressure, which may explain the comparatively limited impact on these outcomes relative to papilledema

FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition

Notably, adherence to the Mediterranean dieta dietary pattern rich in fruits, vegetables, whole grains, olive oil, and lean proteinshas demonstrated significant improvements in hepatic steatosis and insulin resistance among patients with MAFLD [10]

Addressing these challenges while capitalizing on innovations in drug design will be essential for optimizing patient outcomes and realizing the full potential of GLP-1based therapies